{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:49:48Z","timestamp":1761929388963},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T00:00:00Z","timestamp":1228953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective and method\u2002<\/jats:bold> To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high\u2010burden, antimony\u2010resistant area of Northern Bihar, India.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Paromomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119\u2003250 at the current private market price or $64\u2003383\u2013$75\u2003129 at preferential public sector price depending on the size of the order. With AmBisome<jats:sup>\u00ae<\/jats:sup> it would be $163\u2003600 or $229\u2003500 depending on the dose (10 or 15\u2003mg\/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3\u2003weeks for paromomycin; intravenous devices and hospitalization for AmBisome<jats:sup>\u00ae<\/jats:sup>; directly observed treatment if applied for miltefosine) and indirect costs.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> These calculations provide useful basic information for projections.<\/jats:p>","DOI":"10.1111\/j.1365-3156.2008.02195.x","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T14:23:42Z","timestamp":1229005422000},"page":"88-92","source":"Crossref","is-referenced-by-count":29,"title":["Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India"],"prefix":"10.1111","volume":"14","author":[{"given":"P.","family":"Olliaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/519690"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1748"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70296-6"},{"key":"e_1_2_7_5_1","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar S","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021556"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/380971"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066536"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90255-4"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(96)90271-0"},{"key":"e_1_2_7_11_1","volume-title":"WHO\/TDR. Press Release: Elimination of Kala\u2010azar from Endemic Countries in the South\u2010East Asia Region. Health Ministers\u2019 Sign Memorandum of Understanding","author":"WHO","year":"2005"},{"key":"e_1_2_7_12_1","volume-title":"Report of a WHO informal Consultation on \u201cLiposomal Amphotericin B in the Treatment of Visceral Leishmaniasis\u201d","author":"WHO","year":"2005"},{"key":"e_1_2_7_13_1","volume-title":"Leishmaniasis Disease Burden","author":"WHO","year":"2008"},{"key":"e_1_2_7_14_1","volume-title":"Kala Azar: Why Kala Azar Elimination is Possible in South Asia Countries?","author":"WHO","year":"2008"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3156.2008.02195.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3156.2008.02195.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T16:01:37Z","timestamp":1696953697000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3156.2008.02195.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1365-3156.2008.02195.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3156.2008.02195.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}